Mechanisms of recurrence following mRNA-4157 (V940) plus pembrolizumab or pembrolizumab alone in resected melanoma from the mRNA-4157-P201 (KEYNOTE-942) trial

被引：0

作者：

Sullivan, R. J. ^{[1
]}

Lu, M. ^{[2
]}

Koppolu, S. ^{[3
]}

Weber, J. S. ^{[4
]}

Carlino, M. S. ^{[5
,6
]}

Khattak, M. A. ^{[7
,8
]}

Ansstas, G. ^{[9
]}

Taylor, M. H. ^{[10
]}

Mckean, M. ^{[11
]}

Long, G. V. ^{[12
,13
]}

Faries, M. B. ^{[14
]}

Luke, J. J. ^{[15
,16
]}

Sehgal, V. ^{[17
]}

Rao, A. ^{[18
]}

Mao, H. ^{[19
]}

Guo, J. ^{[20
]}

Brown, M. ^{[21
]}

Meehan, R. ^{[22
]}

Feldman, I. ^{[3
]}

Srinivasan, L. ^{[2
]}

机构：

[1] MGH Massachusetts Gen Hosp, Med Oncol Hematol, Boston, MA USA

[2] Moderna Inc, Global Headquarters, Translat Med, Cambridge, MA USA

[3] Moderna Inc, Global Headquarters, Computat Sci, Cambridge, MA USA

[4] NYU Langone Hlth, Laura & Isaac Perlmutter Canc Ctr, New York, NY USA

[5] Melanoma Inst Australia, Med Oncol, Sydney, NSW, Australia

[6] Westmead Hosp, Sydney, NSW, Australia

[7] Hollywood Private Hosp, Oncol, Perth, WA, Australia

[8] Edith Cowan Univ, Perth, WA, Australia

[9] Washington Univ, Sch Med, Oncol, St Louis, MO USA

[10] Earle A Chiles Res Inst, Med Oncol, Portland, OR USA

[11] Sarah Cannon Res Inst, Oncol, Canc Ctr, Nashville, TN USA

[12] Univ Sydney, Melanoma Inst Australia, Royal North Shore, Sydney, NSW, Australia

[13] Mater Hosp, Sydney, NSW, Australia

[14] Angeles Clin & Res Inst, Surg Oncol, Los Angeles, CA USA

[15] UPMC Hillman Canc Ctr, Med Hematol Oncol, Pittsburgh, PA USA

[16] Univ Pittsburgh, Pittsburgh, PA USA

[17] Moderna Inc, Biometr, Global Headquarters, Cambridge, MA USA

[18] Moderna Inc, Clin Biomarkers, Global Headquarters, Cambridge, MA USA

[19] Moderna Inc, Biostat, Global Headquarters, Cambridge, MA USA

[20] Moderna Inc, Biostat & Programming, Global Headquarters, Cambridge, MA USA

[21] Moderna Inc, Clin Dev, Global Headquarters, Cambridge, MA USA

[22] Moderna Inc, Oncol, Global Headquarters, Cambridge, MA USA

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.1166

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1098P

引用

页码：S727 / S728

页数：2

共 16 条

[1] Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial.
Weber, Jeffrey S.
Khattak, Muhammad Adnan
Carlino, Matteo S.
Meniawy, Tarek
Taylor, Matthew H.
Ansstas, George
Kim, Kevin B.
McKean, Meredith
Sullivan, Ryan J.
Faries, Mark B.
Tran, Thuy
Cowey, Charles Lance
Medina, Theresa
Segar, Jennifer Margaret
Atkinson, Victoria
Gibney, Geoffrey Thomas
Luke, Jason J.
Buchbinder, Elizabeth Iannotti
Long, Georgina V.
Meehan, Robert S.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA9512 - LBA9512
[2] Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
Weber, Jeffrey S.
Carlino, Matteo S.
Khattak, Adnan
Meniawy, Tarek
Ansstas, George
Taylor, Matthew H.
Kim, Kevin B.
McKean, Meredith
Long, Georgina, V
Sullivan, Ryan J.
Faries, Mark
Tran, Thuy T.
Cowey, C. Lance
Pecora, Andrew
Shaheen, Montaser
Segar, Jennifer
Medina, Theresa
Atkinson, Victoria
Gibney, Geoffrey T.
Luke, Jason J.
Thomas, Sajeve
Buchbinder, Elizabeth, I
Healy, Jane A.
Huang, Mo
Morrissey, Manju
Feldman, Igor
Sehgal, Vasudha
Robert-Tissot, Celine
Hou, Peijie
Zhu, Lili
Brown, Michelle
Aanur, Praveen
Meehan, Robert S.
Zaks, Tal
LANCET, 2024, 403 (10427): : 632 - 644
[3] mRNA-4157 (V940) individualized neoantigen therapy plus pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response
Weber, J. S.
Khattak, A.
Carlino, M.
Sullivan, R. J.
Luke, J. J.
Meniawy, T.
Taylor, M.
Ansstas, G.
Kim, K.
Mckean, M.
Faries, M.
Tran, T.
Cowey, C. L.
Pecora, A.
Medina, T.
Atkinson, V. G.
Gibney, G.
Buchbinder, E.
Meehan, R.
Long, G. V.
ANNALS OF ONCOLOGY, 2023, 34 : S1288 - S1289
[4] T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
Gainor, Justin F.
Patel, Manish R.
Weber, Jeffrey S.
Gutierrez, Martin
Bauman, Julie E.
Clarke, Jeffrey M.
Julian, Ricklie
Scott, Aaron J.
Geiger, Jessica L.
Kirtane, Kedar
Robert-Tissot, Celine
Coder, Brandon
Tasneem, Moomal
Sun, Jing
Zheng, Wei
Gerbereux, Lauren
Laino, Andressa
Porichis, Filippos
Pollard, Jack Russella
Hou, Peijie
Sehgal, Vasudha
Chen, Xing
Morrissey, Manju
Daghestani, Hikmat N.
Feldman, Igor
Srinivasan, Lakshmi
Frederick, Joshua P.
Brown, Michelle
Aanur, Praveen
Meehan, Robert
Burris III, Howard A.
CANCER DISCOVERY, 2024, 14 (11) : 2209 - 2223
[5] Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial
Khattak, Adnan
Weber, Jeffrey S.
Meniawy, Tarek
Taylor, Matthew H.
Ansstas, George
Kim, Kevin B.
McKean, Meredith
Long, Georgina V.
Sullivan, Ryan J.
Faries, Mark B.
Tran, Thuy
Cowey, Charles Lance
Medina, Theresa Michelle
Segar, Jennifer Margaret
Atkinson, Victoria
Gibney, Geoffrey Thomas
Luke, Jason J.
Buchbinder, Elizabeth Iannotti
Meehan, Robert S.
Carlino, Matteo S.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
[6] Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.
Khattak, Adnan
Weber, Jeffrey S.
Meniawy, Tarek
Taylor, Matthew H.
Ansstas, George
Kim, Kevin B.
McKean, Meredith
Long, Georgina V.
Sullivan, Ryan J.
Faries, Mark B.
Tran, Thuy
Cowey, Charles Lance
Medina, Theresa Michelle
Segar, Jennifer Margaret
Atkinson, Victoria
Gibney, Geoffrey Thomas
Luke, Jason J.
Buchbinder, Elizabeth Iannotti
Meehan, Robert S.
Carlino, Matteo S.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA9503 - LBA9503
[7] INTerpath-001: Pembrolizumab with V940 (mRNA-4157) versus pembrolizumab with placebo for adjuvant treatment of high-risk stage II-IV melanoma
Weber, Jeffrey S.
Luke, Jason J.
Carlino, Matteo S.
Khattak, Muhammad Adnan
Meehan, Robert S.
Brown, Michelle
Zhang, Jinchun
Krepler, Clemens
Duic, J. Paul
Long, Georgina V.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[8] Minimal residual disease by circulating tumor DNA as a biomarker of recurrence free survival in resected high-risk melanoma patients treated with mRNA-4157/V940, a personalized cancer vaccine, and pembrolizumab
Carlino, Matteo S.
Khattak, Adnan
Weber, Jeffrey S.
Meniawy, Tarek
Sullivan, Ryan J.
Taylor, Matthew H.
Kim, Kevin B.
McKean, Meredith
Faries, Mark B.
Cowey, Charles Lance
Gibney, Geoffrey Thomas
Luke, Jason J.
Thomas, Sajeve Samuel
Sehgal, Vasudha
Feldman, Igor
Aanur, Praveen
Brown, Michelle
Meehan, Robert S.
Robert-Tissot, Celine
Long, Georgina V.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
[9] mRNA-4157 (V940) individualized neoantigen therapy (INT) plus pembrolizumab (pembro) in advanced unresectable HPV- head & neck carcinoma (HNSCC): Clinical & translational analysis
Bauman, Julie E.
Julian, Ricklie A.
Geiger, Jessica L.
Mehnert, Janice M.
Clarke, Jeffrey M.
Patel, Manish R.
Gutierrez, Martin
Gainor, Justin F.
Srivats, Shyam
Zhang, Zhaojie
Rao, Anjali
Sehgal, Vasudha
Hou, Peijie
Morrissey, Manju
Feldman, Igor
Srinivasan, Lakshmi
Aanur, Praveen
Brown, Michelle
Meehan, Robert S.
CANCER RESEARCH, 2024, 84 (07)
[10] The phase 3 INTerpath-002 study design: Individualized neoantigen therapy (INT) V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab for resected early-stage non-small-cell lung cancer (NSCLC)
Spicer, Jonathan D.
Nair, Santosh M.
Khattak, Adnan
Lee, Jay M.
Brown, Michelle
Meehan, Robert S.
Shariati, Nazly
Deng, Xuan
Samkari, Ayman
Chaft, Jamie E.
CANCER RESEARCH, 2024, 84 (07)

← 1 2 →